Protocol Ledger

NCT04147208 · Phase II · COMPLETED

Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Interventional Phase II clinical trial protocol NCT04147208 sponsored by Sunshine Lake Pharma Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-28 Enrollment: 250 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04147208
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)250 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04147208
Protocol FieldVerified Registry Value
NCT IdentifierNCT04147208
Consolidated Lead SponsorSunshine Lake Pharma Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment250 participants (ACTUAL)
Registered Start Date2019-02-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI